Measles: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
|||
(25 intermediate revisions by 7 users not shown) | |||
Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Also known as Rubeola | [[File:Koplik's Spots on Cheek.jpg|thumb|Koplik's Spots on Cheek]] | ||
* | [[File:Koplik's Spots on Palate.jpg|thumb|Koplik's Spots on Palate]] | ||
[[File:Measle's Rash on Face.jpg|thumb|Measle's Rash on Face]] | |||
[[File:Measle's Rash on on Thorax.jpg|thumb|Measle's Rash on on Thorax]] | |||
*Also known as Rubeola, which is not to be confused with German Measles ([[Rubella]]) | |||
*Patients are contagious from about 4 days before to 4 days after onset of rash | |||
==Clinical Features== | ==Clinical Features== | ||
* | *Consider measles in a patient of any age who has an acute RASH and FEVER | ||
*Koplik's spots (appears day 2-3) | *Risk factors | ||
**In the prior 3 weeks: travel outside of North America, transit through U.S. international airports, interaction with foreign visitors, including at a U.S. tourist attraction, or travel to areas of the U.S with ongoing measles transmission. | |||
**Confirmed measles cases in your community. | |||
**Never immunized with measles vaccine and born in 1957 or later. | |||
*Incubation period - 10 days | |||
*Prodrome of high [[fever]], [[cough]], coryza, and [[conjunctivitis]] (lasts ~3 days) | |||
*Koplik's spots (appears day 2-3) - pathognomonic enanthem | |||
**Tiny red spots (base) with bluish-white centers on the mucosa of the cheek or palate | **Tiny red spots (base) with bluish-white centers on the mucosa of the cheek or palate | ||
*Rash (begins day 4 - lasts to day 7) | *[[Rash]] (begins day 4 - lasts to day 7) | ||
** | **Red, blotchy, and maculopapular; rapidly progresses to confluence | ||
**Usually starts on the face (hairline and behind the ears) | **Usually starts on the face (hairline and behind the ears) | ||
**Rapidly spreads to the chest, back, and finally the legs and feet | **Rapidly spreads to the chest, back, and finally the legs and feet | ||
* | **Rash resolves in order of appearance between days 7-9 | ||
[[ | ===Complications=== | ||
[[ | *Secondary infection | ||
[[ | **Measles virus can directly infect T cells, leading to systemic immune suppression and secondary infections | ||
[[ | *Gastrointestinal | ||
**[[Diarrhea]] is the most common complication | |||
** Others: gingivostomatitis, [[gastroenteritis]], [[hepatitis]], mesenteric lymphadenitis, and [[appendicitis]] | |||
*Pulmonary | |||
**Pneumonia is the most common cause of measles-associated death in children | |||
*Neurologic | |||
**[[Encephalitis]] | |||
**Acute disseminated encephalomyelitis | |||
***Demyelinating disease thought to be a postinfectious autoimmune response | |||
**Subacute sclerosing panencephalitis | |||
***A fatal, progressive degenerative disease of the CNS that usually occurs 7 to 10 years after natural measles virus infection | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
{{Peds Rash DDX}} | {{Peds Rash DDX}} | ||
== | {{DDX oral rashes and lesions}} | ||
* | ==Evaluation== | ||
* | ===Workup=== | ||
''Initial treatment/isolation is based on clinical suspicion; testing is normally performed in conjunction with recommendations by local public health experts<ref name="CA Advisory 4-2019">California Department of Public Health Health Advisory: Measles Clinical Guidance: Identification and Testing of Suspect Measles Cases. April 3, 2019</ref>'' | |||
*PCR is the preferred testing method for measles, and can only be performed in public health laboratories.<ref name="CA Advisory 4-2019">California Department of Public Health Health Advisory: Measles Clinical Guidance: Identification and Testing of Suspect Measles Cases. April 3, 2019</ref> | |||
*Measles IgM testing is frequently falsely positive and is not recommended<ref name="CA Advisory 4-2019">California Department of Public Health Health Advisory: Measles Clinical Guidance: Identification and Testing of Suspect Measles Cases. April 3, 2019</ref> | |||
===Diagnosis<ref name="CA Advisory 4-2019">California Department of Public Health Health Advisory: Measles Clinical Guidance: Identification and Testing of Suspect Measles Cases. April 3, 2019</ref>=== | |||
Providers should consider measles in patients with FEVER AND a descending RASH in a person with a history of travel or contact with someone who has travelled outside North America <u>whether or not the patient has had 2 doses of MMR or prior measles disease</u>. However, persons without a history of travel or exposure to a traveler, are unlikely to have measles in the absence of confirmed measles cases in your community. | |||
==Management== | ==Management== | ||
* | *Supportive care | ||
=== | ===Suspected Active Measles Case<ref name="CA Advisory 4-2019">California Department of Public Health Health Advisory: Measles Clinical Guidance: Identification and Testing of Suspect Measles Cases. April 3, 2019</ref>=== | ||
#Isolate patient immediately (see below) | |||
#Alert your local health department immediately | |||
* | #*The risk of measles transmission to others and large contact investigations can be reduced if control measures are implemented immediately | ||
#If advised to test for measles by your local health department, submit a specimen for polymerase chain reaction (PCR) testing (see Workup section above). | |||
=== | ===[[Isolation precautions|Isolation Precautions]]=== | ||
*For suspected patients | *For suspected patients | ||
** | **Mask the patient and isolate immediately in an airborne infection isolation room | ||
**All personnel entering the room should use respiratory protection at least as effective as an N95 respirator | **All personnel entering the room should use respiratory protection at least as effective as an N95 respirator | ||
**If possible, allow only personnel with documentation of 2 doses of live measles vaccine or laboratory evidence of immunity (measles IgG positive) to enter the room | **If possible, allow only personnel with documentation of 2 doses of live measles vaccine or laboratory evidence of immunity (measles IgG positive) to enter the room | ||
**Do not use the room for at least 2 hours after the patient leaves. | **Do not use the room for at least 2 hours after the patient leaves. | ||
===Post-Exposure Prophylaxis (Non-Immune Contact)=== | |||
*Immunocompetent: | |||
**MMR Vaccine (within 72 hours of exposure) | |||
*Immunocompromised, children <12 months, and others at high risk of complications: | |||
**IM Immune globulin (up to 6 days after exposure) | |||
**Consider checking with your local health authorities | |||
==Disposition== | |||
*Discuss with public health | |||
**Patients may be admitted with isolation to prevent public health spread vs. discharged with home isolation precautions | |||
==See Also== | ==See Also== | ||
*[[Pediatric Rashes]] | *[[Pediatric Rashes]] | ||
== | ==External Links== | ||
* | *Guidance from CDC for healthcare professionals: https://www.cdc.gov/measles/hcp/index.html | ||
*CDC clinical syndromes: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html | |||
==References== | |||
<references/> | |||
[[Category:ID]] | [[Category:ID]] | ||
[[Category: | [[Category:Dermatology]] | ||
[[Category: | [[Category:Pediatrics]] |
Revision as of 01:12, 15 September 2019
Background
- Also known as Rubeola, which is not to be confused with German Measles (Rubella)
- Patients are contagious from about 4 days before to 4 days after onset of rash
Clinical Features
- Consider measles in a patient of any age who has an acute RASH and FEVER
- Risk factors
- In the prior 3 weeks: travel outside of North America, transit through U.S. international airports, interaction with foreign visitors, including at a U.S. tourist attraction, or travel to areas of the U.S with ongoing measles transmission.
- Confirmed measles cases in your community.
- Never immunized with measles vaccine and born in 1957 or later.
- Incubation period - 10 days
- Prodrome of high fever, cough, coryza, and conjunctivitis (lasts ~3 days)
- Koplik's spots (appears day 2-3) - pathognomonic enanthem
- Tiny red spots (base) with bluish-white centers on the mucosa of the cheek or palate
- Rash (begins day 4 - lasts to day 7)
- Red, blotchy, and maculopapular; rapidly progresses to confluence
- Usually starts on the face (hairline and behind the ears)
- Rapidly spreads to the chest, back, and finally the legs and feet
- Rash resolves in order of appearance between days 7-9
Complications
- Secondary infection
- Measles virus can directly infect T cells, leading to systemic immune suppression and secondary infections
- Gastrointestinal
- Diarrhea is the most common complication
- Others: gingivostomatitis, gastroenteritis, hepatitis, mesenteric lymphadenitis, and appendicitis
- Pulmonary
- Pneumonia is the most common cause of measles-associated death in children
- Neurologic
- Encephalitis
- Acute disseminated encephalomyelitis
- Demyelinating disease thought to be a postinfectious autoimmune response
- Subacute sclerosing panencephalitis
- A fatal, progressive degenerative disease of the CNS that usually occurs 7 to 10 years after natural measles virus infection
Differential Diagnosis
Pediatric Rash
- Atopic dermatitis
- Bed bugs
- Contact dermatitis
- Drug rash
- Erythema infectiosum (Fifth disease)
- Hand-foot-and-mouth disease
- Henoch-schonlein purpura (HSP)
- Herpangina
- Herpes simplex virus (HSV)
- Infectious mononucleosis
- Meningitis
- Measles
- Molluscum contagiosum
- Roseola infantum
- Rubella (German measles)
- Scabies
- Scarlet fever
- Smallpox
- Varicella (Chickenpox)
Oral rashes and lesions
- Angioedema
- Aphthous stomatitis
- Herpes gingivostomatitis
- Herpes labialis
- Measles (Koplik's spots)
- Perioral dermatitis
- Oral thrush
- Steven Johnson syndrome
- Streptococcal pharyngitis
- Tongue diagnoses
- Vincent's angina
Evaluation
Workup
Initial treatment/isolation is based on clinical suspicion; testing is normally performed in conjunction with recommendations by local public health experts[1]
- PCR is the preferred testing method for measles, and can only be performed in public health laboratories.[1]
- Measles IgM testing is frequently falsely positive and is not recommended[1]
Diagnosis[1]
Providers should consider measles in patients with FEVER AND a descending RASH in a person with a history of travel or contact with someone who has travelled outside North America whether or not the patient has had 2 doses of MMR or prior measles disease. However, persons without a history of travel or exposure to a traveler, are unlikely to have measles in the absence of confirmed measles cases in your community.
Management
- Supportive care
Suspected Active Measles Case[1]
- Isolate patient immediately (see below)
- Alert your local health department immediately
- The risk of measles transmission to others and large contact investigations can be reduced if control measures are implemented immediately
- If advised to test for measles by your local health department, submit a specimen for polymerase chain reaction (PCR) testing (see Workup section above).
Isolation Precautions
- For suspected patients
- Mask the patient and isolate immediately in an airborne infection isolation room
- All personnel entering the room should use respiratory protection at least as effective as an N95 respirator
- If possible, allow only personnel with documentation of 2 doses of live measles vaccine or laboratory evidence of immunity (measles IgG positive) to enter the room
- Do not use the room for at least 2 hours after the patient leaves.
Post-Exposure Prophylaxis (Non-Immune Contact)
- Immunocompetent:
- MMR Vaccine (within 72 hours of exposure)
- Immunocompromised, children <12 months, and others at high risk of complications:
- IM Immune globulin (up to 6 days after exposure)
- Consider checking with your local health authorities
Disposition
- Discuss with public health
- Patients may be admitted with isolation to prevent public health spread vs. discharged with home isolation precautions
See Also
External Links
- Guidance from CDC for healthcare professionals: https://www.cdc.gov/measles/hcp/index.html
- CDC clinical syndromes: https://www.cdc.gov/vaccines/pubs/pinkbook/meas.html